全膝关节置换术后假体周围感染患者死亡率的Meta分析
该Meta分析纳入39项研究共83,353例全膝关节置换术后假体周围感染患者,平均随访4.4年,总体死亡率为13.3%(95%CI 8.8至18.5)。不同手术治疗方式间死亡率差异显著(p<0.001),DAIR为12.3%,一期翻修为0.47%,二期翻修为11.5%。
要点
- TKA术后PJI总体死亡率为13.3%,平均随访4.4年。
- 不同手术方式死亡率差异显著:DAIR 12.3%,一期翻修0.47%,二期翻修11.5%。
- DAIR与二期翻修在3个月和12个月死亡率无显著差异。
核心结论
- TKA术后PJI患者死亡率仍较高,超过乳腺癌和前列腺癌患者的五年死亡率。
- PJI负担需要多学科协作和专项资助以改善患者照护并降低死亡率。
研究设计与样本
- 系统检索Ovid MEDLINE、Embase、CINAHL、Cochrane Library、Scopus和Web of Science至2023年12月。
- 纳入报告TKA术后PJI患者死亡率的全文研究,排除肿瘤、创伤或化脓性关节炎指征的TKA及部分或翻修TKA。
- 排除主要纳入高风险患者(如器官移植或癌症)的研究,以评估常规临床实践中的死亡率。
- 采用随机效应估计器的比例Meta分析报告死亡率,遵循2020 PRISMA指南。
主要发现
- 共纳入39项研究、83,353例TKA术后PJI患者,平均随访4.4年(1个月至17年)。
- TKA术后PJI总体死亡率为13.3%(95%CI 8.8至18.5)。
- 3个月、12个月和24个月死亡率分别为4.8%(95%CI 1.2至18.0)、7.0%(95%CI 2.2至29.9)和6.4%(95%CI 3.0至46.0)。
- 不同手术方式间死亡率差异显著(p<0.001):DAIR 12.3%(95%CI 3.9至24.0),一期翻修0.47%(95%CI 0至1.5),二期翻修11.5%(95%CI 8.5至15.0)。
- DAIR与二期翻修患者在3个月和12个月死亡率无显著差异。
关键数值与推荐
- TKA术后PJI总体死亡率为13.3%(95%CI 8.8至18.5)。
- 3个月、12个月和24个月死亡率分别为4.8%、7.0%和6.4%。
- DAIR死亡率12.3%,一期翻修0.47%,二期翻修11.5%,组间差异p<0.001。
临床怎么用
- 临床应重视TKA术后PJI患者的高死亡风险,尤其在长期随访中。
- 选择手术方式时需考虑不同术式相关的死亡率差异,但需结合患者具体情况。
- 建议采取多学科协作模式管理PJI以改善预后。
局限性
- 原文未报告纳入研究的异质性定量指标(如I²)。
- 原文未报告发表偏倚评估结果。
- 部分亚组分析的置信区间较宽,提示估计值不确定性较大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to evaluate the overall mortality rate in patients with periprosthetic joint infection (PJI) after total knee arthroplasty (TKA), the overall mortality over time, and mortality after treatment. METHODS: Ovid MEDLINE, Embase, CINAHL, Cochrane Library, Scopus, and Web of Science, were searched for studies reporting the rate of mortality in patients with TKA PJI until December 2023. Full-length studies with extractable data dealing with mortality in these patients were included. Studies were excluded if they involved TKAs which were undertaken for oncological or traumatic indications or septic arthritis, or were partial or revision TKAs. Studies in which primarily high-risk patients, such those with an organ transplant or cancer, were also excluded, in order to allow the mortality rate in patients with PJI after TKA in routine clinical practice to be evaluated. Data were abstracted using a standardized form. Meta-analyses of the proportions with random-effects estimators were used to report the mortality rate after TKA PJI, over time, and after treatment. The study adhered to the 2020 PRISMA guidelines. RESULTS: A total of 83,353 patients with a PJI after TKA from 39 studies were included. At a mean follow-up of 4.4 years (1 month to 17 years), the overall mortality rate after TKA PJI was 13.3% (95% CI 8.8 to 18.5). It was 4.8% (1.2 to 18.0), 7.0% (2.2 to 29.9), and 6.4% (3.0 to 46.0) at three, 12, and 24 months, respectively. The rate significantly differed between the different forms of surgical treatment for PJI (p < 0.001): debridement, antibiotics, and implant retention (DAIR) 12.3% (95% CI 3.9 to 24.0); one-stage exchange arthroplasty 0.47% (95% CI 0 to 1.5); and two-stage exchange arthroplasty 11.5% (95% CI 8.5 to 15.0). There were no significant differences in the mortality rate between patients treated with DAIR and those who underwent a two-stage exchange arthroplasty at three and 12 months. CONCLUSION: Mortality after TKA PJI remains high, surpassing the five-year rates of mortality in patients with cancer of the breast and prostate. The burden associated with PJI necessitates a multidisciplinary approach and dedicated funding to improve patient care, address this critical issue generally, and reduce mortality.
引用
- Ramos MS, Benyamini B, Kompala V, et al. Mortality after an infected total knee arthroplasty : a meta-analysis. Bone Joint J. 2026. PMID: 41619799. doi:10.1302/0301-620X.108B2.BJJ-2025-0106.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。